American Journal of Hematology

Article	Citations
Issue Information	498
	276
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	259
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	159
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	156
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	154
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	147
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	135
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	120
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	112
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	102
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	95
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	94
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	88
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	86
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	73
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	72
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	71
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	71
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	68
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	68
Are veterans at increased risk of myeloproliferative neoplasms?	64
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	64
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	63
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	62

Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	62
Acute thrombocytopenia suggesting thrombotic microangiopathy	60
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	58
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	57
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	55
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	55
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	55
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	53
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	51
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	50
Molecular and clinicopathologic characterization of pediatric histiocytoses	50
Teclistamab in patients with multiple myeloma and impaired renal function	50
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	50
The latest insights into rare blood disorders: Diagnosis and treatment strategies	48
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	48
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	47
Table of Contents	46
Clonal Hematopoiesis and Thrombosis	46
	45
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	45
Impact of Switching From Race‐Based to Race‐Neutral Spirometry Reference Equations in Children With Sickle Cell Anemia	45
Quick consults in hematology: Staging and treating immunoglobulin light chain (AL) amyloidosis	44
Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia	42
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018)	40
Peak absolute lymphocyte count after CAR‐T infusion predicts clinical response in aggressive lymphoma	40
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurre	40
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease‐positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial	38
International Consensus Classification for myeloid neoplasms at‐a‐glance	37
Rare circulating lymphoblasts with striking eosinophilia: A rare case of B‐lymphoblastic leukemia with PAX5::ZCCHC7	37
Impaired pro‐resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease	37
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	36
A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficien	36
Novel, de novo, beta‐globin variant with decreased oxygen affinity (HBB:c.317T>A, “Hemoglobin St. George”) in a healthy child with low oxygen saturations and ane	36
Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study	35
Donor Age Matters for Haploidentical HCT Patients Even After Adjusting for HLA Factors: A Machine Learning Approach	35
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients	35
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	35
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource	34
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants	34
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	33
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring	33
Toward an improved understanding of hypomethylating agent and venetoclax therapies	33
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	33
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	32
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	32
Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases	32
A genomic‐augmented multivariate prognostic model for the survival of natural‐killer/T‐cell lymphoma patients from an international cohort	32
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (	32
Hydroxyurea in pregnancy: Reframing the conversation	32
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy	31

Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)	31
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient	31
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	31
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial	30
Different impacts of granulocyte colony‐stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type	30
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real‐world retrospective multi‐institutional cohort	30
POEMS syndrome: Update on diagnosis, risk‐stratification, and management	30
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis	30
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy	30
Myelokathexis in an 18‐year‐old male patient with severe neutropenia and lymphopenia	30
Six‐week low‐molecular‐weight heparin versus 12‐week warfarin for calf deep vein thrombosis: A randomized, prospective, open‐label study	29
Issue Information	29
Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation	29
The Diversity of Spiculated Erythrocytes	29
The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study	28
TACI variants as underlying condition in autoimmune neutropenia: Description of four cases	28
Primary myelofibrosis in a patient with sickle cell disease	28
Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study	28
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors	28
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies	28
Transient receptor potential channel vanilloid type 2 in red cells of cannabis consumer	28
Elevated MCHC reveals a Southeast Asian Ovalocytosis	28
Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis	28
A case of peripheral T‐cell lymphoma, NOS, mimicking acute monocytic leukemia	28
Thirteen‐month‐old girl with hyporegenerative macrocytic anemia due to Brown–Vialetto–Van Laere syndrome 2	27
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy	27
Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort	27
Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma	27
Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?	27
A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia	27
LLM Abstracts Supplement	26
Hemolytic anemia and macrothrombocytopenia: A lipid problem?	26
Pearson syndrome	26
Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia—aCML)	26
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia	26
Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma	26
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma	25
Tissue factor activity is increased in neutrophils from JAK2 V617F‐mutated essential thrombocythemia and polycythemia vera patients	25
Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort Study	25
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	25
A Case of Hodgkin Lymphoma in a Gaucher Disease Patient: Distinguishing Gaucher and Pseudo‐Gaucher Cells	25
Moderate–severe beta‐thalassemia intermedia phenotype caused by sextuplicated alpha‐globin gene allele in two beta‐thalassemia carriers	25
Combination of Biological Aging and Genetic Susceptibility Helps Identifying At‐Risk Population of Venous Thromboembolism: A Prospective Cohort Study of 394 041 Participants	25
Clinical Factors Associated With Catheter‐Related VTE in Patients Undergoing Hematopoietic Cell Transplantation: A Multi‐Center Study	25
Correction to “Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B‐Cell Lymp	24
Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study	24
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic	24
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	24
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria	24
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia	24
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	24
	23
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia	23
Issue Information	23
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management	23
Table of Contents	23
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	23
Therapeutic Advances and Future of Therapy in Acute Myeloid Leukemia	22
Identification of a CAR‐Derived Clone by NGS‐Based MRD After Fully Human BCMA CAR T‐Cell Therapy in Multiple Myeloma	22
SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers	22
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial	22
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia	22
SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey	21
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study	21
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept	21
Evaluating ChatGPT as an educational resource for patients with multiple myeloma: A preliminary investigation	21
Unusual complications in the management of chronic lymphocytic leukemia	21
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by	21
Peripheral CD5+ CD10+ B‐cell proliferation with atypical morphology attributable to human herpesvirus 6 infection following umbilical cord blood transplantation	21
The pleiotropic effects of α‐thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co‐transport activity, serum erythropoietin, and transfusion burden, do	21
The MAGIC algorithm probability (MAP)‐guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial	21
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph‐positive leukemias	21
Myopathy related to chronic Graft‐Versus‐Host Disease: From clinic to histological & immunological characterization by imaging mass cytometry	20
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial	20
Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis	20
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated mult	20
TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis	20
Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma	20
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia	20
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms	19

2025 update on clinical trials in immune thrombocytopenia	19
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma	19
Correction to “Efficacy and Safety of Early‐Start Deferiprone in Infants and Young Children With Transfusion‐Dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin in a Randomized, Dou	19
Generating Off‐the‐Shelf Hematopoietic Stem Cells by “Stretching” Induced Pluripotent Stem Cells	19
Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial	19
‘Phenoconversion’ in adult patients with β‐thalassemia	19
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition	19
Table of Contents	18
Management of post‐autologous transplant relapse in patients with T‐cell lymphomas	18
Space anemia unexplained: Red blood cells seem to be space‐proof	18
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?	18
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing	18
RETRACTION: A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation	18
Acute hemolytic anemia after hematopoietic stem cell transplantation: An unusual invader	18
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies	18
A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa	18
Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients	18
Issue Information	18
A 29‐gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival	18
High incidence of malaria in patients with sickle cell disease	18
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies	17
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	17
Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan	17
Hyperparathyroidism and the Hematologist	17
Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP: A multicenter, randomized, controlled study	17
Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study	17
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	17
Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort	17
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	17
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study	17
ALK‐positive histiocytosis of external auditory canal in a 3‐year‐old boy	17
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	17
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase	17
Peripheral blood evidence of iron overload	17
Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia	16
JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: Splenectomy or radiotherapy?	16
Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria	16
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA	16
Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease	16
Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features	16
Complement biology for hematologists	16
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple	16
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or	16
Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology	16
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	16
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?	16
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	16
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes	16
Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura?	15
	15
Thalassemia enters a new age … And more lies ahead	15
Increased risk of venous thromboembolism in patients with gastrointestinal disorders	15
Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable	15
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort	15
	15
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	15
	15
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	15
	15
Poor Engraftment After Posttransplant Cyclophosphamide Graft‐Versus‐Host Disease Prophylaxis in Patients With Myelofibrosis	15
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis”	15
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	15
Characterization of the human ABO genotypes and their association to common inflammatory and cardiovascular diseases in the UK Biobank	15
	15
Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7‐targeted Chimeric Antigen R	15
Issue Information	15
The prognostic value of blood cellular indices in pulmonary embolism	15
TRAF3 alterations are frequent in del‐3′IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features	14
Issue Information	14
Fulminant intravascular hemolysis resulting from Clostridium perfringens infection	14
Changing hemostatic management in post‐partum hemorrhage	14
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy	14
Inherited thrombophilia gene mutations and risk of venous thromboembolism in patients with cancer: A systematic review and meta‐analysis	14
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia	14
Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment	14
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring	14
Phase II clinical trial of one dose of post‐transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched‐unrelated donor	14
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	14
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON	14
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms	14
DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1	14
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review	14
Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators	14
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study	14
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study	14
Rate of major bleeding with ibrutinib versus bendamustine‐rituximab in chronic lymphocytic leukemia: A population‐based cohort study	14
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria	14
Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia	14
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases	14
Crystal‐storing lymphocytosis	14
Residual Cerebrovascular Morbidity Despite Treatment in Pediatric Sickle Cell Disease Highlights Opportunities for Earlier, Intensified Monitoring and Treatment	14
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	14
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria	14
Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease	13
Artificial intelligence generated leukemia cell images	13